Journals / Güncel Retina Dergisi / 2022 / Cilt: 6 - Sayı: 2

Other Hereditary Syndromes Associated with Secondary Optic Atrophy

İkincil Optik Atrofi ile İlişkili Diğer Kalıtsal Sendromlar

Pages
113–117
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cellular disorder is reflected in the phenotype by affecting the related intracellular chemical reaction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Optic neuropathy is a cause that seriously impairs vision loss, which we frequently encounter in ophthalmology practice.
📊
Key Findings & Data:Although it is frequently seen with eye diseases such as glaucoma, it can also be seen together with systemic neurodegenerative syndromes.
💡
Conclusion & Impact:Cellular disorder is reflected in the phenotype by affecting the related intracellular chemical reaction.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Optic neuropathy is a cause that seriously impairs vision loss, which we frequently encounter in ophthalmology practice. Although it is frequently seen with eye diseases such as glaucoma, it can also be seen together with systemic neurodegenerative syndromes. In this review, we have included some rare syndromes that cause genetically inherited optic atrophy. In these syndromes, the structure of the encoded proteins is disrupted as a result of mutated genes. Cellular disorder is reflected in the phenotype by affecting the related intracellular chemical reaction.

Özet

Optik nöropati, oftalmoloji pratiğinde sıklıkla rastladığımız, görme kaybını ciddi şekilde bozan bir nedendir. Sıklıkla glokom gibi göz hastalıklarıyla birlikte görülse de sistemik nörodejeneratif sendromlarla da birlikte görülebilmektedir. Bu derlemede nadir görülen, genetik geçişli optik atrofiye sebep olan bazı sendromlara yer verdik. Bu sendromlarda mutasyona uğrayan genler sonucunda kodlanan proteinlerin yapısı bozulur. İlgili hücre içi kimyasal reaksiyonun etkilenmesiyle hücresel bozukluk fenotipe yansır.

🔖

Cite This Article

KARAMAN, S. K. (2022). Other Hereditary Syndromes Associated with Secondary Optic Atrophy. Güncel Retina Dergisi, Cilt: 6 - Sayı: 2, 113–117. https://ajindex.com/articles/528146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kim K, Kleinman HK, Lee HJ, Pahan K. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017;12(1):113
  2. Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2009;1793(4):697-709
  3. Kohlschutter A, Schulz A. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis). Pediatr Endocrinol Rev. 2016;13 Suppl 1:682-8
  4. Kohlschutter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33(4):315-25
  5. Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Holthaus S-MK, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. The Lancet Neurology. 2019;18(1):107-16
  6. Katz ML, Rustad E, Robinson GO, Whiting REH, Student JT, Coates JR, et al. Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions. Neurobiol Dis. 2017;108:277-87
  7. Chang X, Huang Y, Meng H, Jiang Y, Wu Y, Xiong H, et al. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses. Brain Dev. 2012;34(9):739-45
  8. Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161-78
  9. Manara R, D’Agata L, Rocco MC, Cusmai R, Freri E, Pinelli L, et al. Neuroimaging Changes in Menkes Disease, Part 1. AJNR Am J Neuroradiol. 2017;38(10):1850-7
  10. Manara R, Rocco MC, D’Agata L, Cusmai R, Freri E, Giordano L, et al. Neuroimaging Changes in Menkes Disease, Part 2. AJNR Am J Neuroradiol. 2017;38(10):1858-65
  11. Ackerman CM, Weber PK, Xiao T, Thai B, Kuo TJ, Zhang E, et al. Multimodal LA-ICP-MS and nanoSIMS imaging enables copper mapping within photoreceptor megamitochondria in a zebrafish model of Menkes disease. Metallomics. 2018;10(3):474-85
  12. Ogata R, Chong PF, Maeda K, Imagi T, Nakamura R, Kawamura N, et al. Long surviving classical Menkes disease treated with weekly intravenous copper therapy. J Trace Elem Med Biol. 2019;54:172-4
  13. Vairo FPE, Chwal BC, Perini S, Ferreira MAP, de Freitas Lopes AC, Saute JAM. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Mol Genet Metab. 2019;126(1):6-13
  14. Stern BR, Solioz M, Krewski D, Aggett P, Aw TC, Baker S,